IL251799B2 - Serpin fusion polypeptides and methods of use thereof - Google Patents
Serpin fusion polypeptides and methods of use thereofInfo
- Publication number
- IL251799B2 IL251799B2 IL251799A IL25179917A IL251799B2 IL 251799 B2 IL251799 B2 IL 251799B2 IL 251799 A IL251799 A IL 251799A IL 25179917 A IL25179917 A IL 25179917A IL 251799 B2 IL251799 B2 IL 251799B2
- Authority
- IL
- Israel
- Prior art keywords
- methods
- fusion polypeptides
- serpin fusion
- serpin
- polypeptides
- Prior art date
Links
- 102000008847 Serpin Human genes 0.000 title 1
- 108050000761 Serpin Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003001 serine protease inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
| PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL251799A0 IL251799A0 (en) | 2017-06-29 |
| IL251799B1 IL251799B1 (en) | 2023-12-01 |
| IL251799B2 true IL251799B2 (en) | 2024-04-01 |
Family
ID=55858243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251799A IL251799B2 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
| IL308589A IL308589A (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308589A IL308589A (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3212290A4 (en) |
| JP (2) | JP6737781B2 (en) |
| KR (2) | KR20240005109A (en) |
| CN (2) | CN107206257A (en) |
| AU (2) | AU2015339507B2 (en) |
| BR (1) | BR112017008525A2 (en) |
| CA (1) | CA2965151A1 (en) |
| HK (1) | HK1244460A1 (en) |
| IL (2) | IL251799B2 (en) |
| MX (2) | MX2017005467A (en) |
| RU (1) | RU2746550C2 (en) |
| SG (2) | SG10201903142RA (en) |
| UA (1) | UA127305C2 (en) |
| WO (1) | WO2016069574A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021008200A2 (en) * | 2018-10-29 | 2021-12-14 | Spin Therapeutics Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| WO2020097946A1 (en) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | Recombinant human interleukin-10 fusion protein and application thereof |
| CN112315897A (en) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | Polymer microneedle for treating acute gout attack by inhibiting release of cell inflammatory reaction and preparation method |
| US20240067703A1 (en) * | 2020-12-21 | 2024-02-29 | Macquarie University | Treatment of glaucoma |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| AU2022230745A1 (en) * | 2021-03-03 | 2023-08-17 | Formycon Ag | Formulations of ace2 fc fusion proteins |
| CN113325181A (en) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | Application of serine protease inhibitor in marker for early warning of sepsis |
| CN114874333A (en) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | Growth hormone fusion protein and application thereof |
| US20230364208A1 (en) | 2022-05-16 | 2023-11-16 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3609300A (en) * | 1999-03-01 | 2000-09-21 | Human Genome Sciences, Inc. | Human serpin proteins |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1646642A2 (en) * | 2003-07-18 | 2006-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| EP2520654B8 (en) * | 2003-08-26 | 2017-04-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| DK1817340T3 (en) * | 2004-11-12 | 2012-08-13 | Xencor Inc | FC VARIATIONS WITH CHANGED BINDING TO FCRN |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007014123A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| EP1926747A1 (en) * | 2005-08-12 | 2008-06-04 | Schering Corporation | Mcp1 fusions |
| AU2009262199B2 (en) * | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CN106432503B (en) * | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
| MX347077B (en) * | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants. |
| EP3590965A1 (en) * | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| CN110551223A (en) * | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | Serine protease inhibitor protein fusion polypeptides and methods of use thereof |
| MX356433B (en) * | 2011-06-28 | 2018-05-29 | Inhibrx Lp | Wap domain fusion polypeptides and methods of use thereof. |
| KR102348985B1 (en) * | 2012-01-10 | 2022-01-12 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| JP2015531748A (en) * | 2012-06-21 | 2015-11-05 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Incretin receptor ligand polypeptide FC region fusion polypeptide and complex having modified FC effector function |
| WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| DK2880170T3 (en) * | 2012-08-02 | 2016-10-24 | Hoffmann La Roche | PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF |
| EP2929045B1 (en) * | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
-
2015
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/en active Pending
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/en active Application Filing
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/en unknown
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/en not_active IP Right Cessation
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/en active Search and Examination
- 2015-10-27 UA UAA201705128A patent/UA127305C2/en unknown
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/en active Active
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/en active
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/en active Pending
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/en unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/en unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/en active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017118325A3 (en) | 2019-03-21 |
| IL308589A (en) | 2024-01-01 |
| CN107206257A (en) | 2017-09-26 |
| WO2016069574A1 (en) | 2016-05-06 |
| JP2020180157A (en) | 2020-11-05 |
| IL251799B1 (en) | 2023-12-01 |
| IL251799A0 (en) | 2017-06-29 |
| MX2021012047A (en) | 2021-11-03 |
| KR20240005109A (en) | 2024-01-11 |
| CN114316068A (en) | 2022-04-12 |
| CA2965151A1 (en) | 2016-05-06 |
| EP3212290A4 (en) | 2019-01-23 |
| AU2015339507A1 (en) | 2017-05-11 |
| JP2017537888A (en) | 2017-12-21 |
| SG10201903142RA (en) | 2019-05-30 |
| RU2017118325A (en) | 2018-11-29 |
| JP6737781B2 (en) | 2020-08-12 |
| EP3212290A1 (en) | 2017-09-06 |
| BR112017008525A2 (en) | 2018-01-30 |
| MX2017005467A (en) | 2017-11-30 |
| UA127305C2 (en) | 2023-07-19 |
| KR20170091096A (en) | 2017-08-08 |
| HK1244460A1 (en) | 2018-08-10 |
| AU2021240153A1 (en) | 2021-10-28 |
| SG11201703390SA (en) | 2017-05-30 |
| RU2746550C2 (en) | 2021-04-15 |
| AU2015339507B2 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275307B (en) | Syntac polypeptides and uses thereof | |
| IL281273A (en) | Modified fgf-21 polypeptides and uses thereof | |
| HRP20190028T1 (en) | Interleukin-2 fusion proteins and uses thereof | |
| IL250415B (en) | Anti-pdl- antibodies and methods of use thereof | |
| GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
| IL262727A (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| HK1244460A1 (en) | Serpin fusion polypeptides and methods of use thereof | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| EP3349851A4 (en) | Light-responsive polypeptides and methods of use thereof | |
| EP3092248A4 (en) | Fusion polypeptides and methods of use | |
| GB201410031D0 (en) | Polypeptides and uses thereof | |
| EP3322736A4 (en) | Fusion polypeptides and methods of use | |
| IL247448A0 (en) | Peptides and methods of use | |
| RS62066B1 (en) | Modified fgf-21 polypeptides and uses thereof |